Comparative Pharmacology
Head-to-head clinical analysis: LORCET HD versus LORTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORCET HD versus LORTAB.
LORCET-HD vs LORTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist, modulating pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways, providing antipyretic and analgesic effects.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates pain pathways centrally.
1-2 tablets (hydrocodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4 g/day (or 3 g/day in at-risk patients).
1-2 tablets (each containing 5 mg hydrocodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain. Maximum acetaminophen 3000 mg/day.
None Documented
None Documented
Morphine: 2-4 hours; hydrocodone: 3.8-6 hours. Clinical context: Immediate-release, dosing every 4-6 hours.
Hydrocodone: 3.3-4.4 hours in adults; prolonged in hepatic/renal impairment (up to 6-8 hours). Clinical context: requires 4-6 hour dosing intervals; steady-state in ~24 hours.
Renal: 90% as morphine-3-glucuronide and morphine-6-glucuronide, 10% as unchanged morphine; biliary: minor (<5%); fecal: <5%.
Renal: ~90% (unchanged: ~5% hydrocodone, ~60% hydromorphone and other conjugates; codeine-like metabolites). Biliary/fecal: minor (<10%).
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination